Radical Cystectomy Explained
Radical cystectomy is major surgery to remove the urinary bladder, usually together with pelvic lymph nodes, for muscle-invasive bladder cancer or selected very-high-risk non-muscle-invasive disease. Because the bladder is removed, the operation also creates a urinary diversion — most commonly an ileal conduit with a stoma or an orthotopic neobladder in carefully selected patients. In men, the prostate and seminal vesicles are commonly removed with the bladder; in women, the extent of adjacent organ removal is individualized and organ-sparing approaches may be possible in selected cases. Recovery takes weeks to months and requires attention to nutrition, bowel function, mobility, blood-clot prevention, kidney function and adaptation to the new urinary system.
Who may need radical cystectomy?
- Muscle-invasive bladder cancer suitable for curative surgery.
- Very-high-risk non-muscle-invasive bladder cancer where progression risk is substantial.
- BCG-unresponsive high-grade NMIBC in a fit patient.
- Recurrent or refractory high-grade disease not safely controlled with bladder-preserving treatment.
- Selected non-urothelial bladder cancers where surgery is the main local treatment.
What is removed?
The exact operation depends on sex, tumour location and cancer extent. The bladder and regional pelvic lymph nodes are removed. In men, the prostate and seminal vesicles are usually included. In women, removal of the uterus, ovaries, part of the vagina or urethra is not automatically required in every modern operation; organ-sparing can be considered when oncologically safe and technically appropriate.
How does urine leave the body afterward?
| Diversion | How it works | Main practical issue |
|---|---|---|
| Ileal conduit | Short segment of small bowel carries urine from ureters to a stoma on the abdomen | External urostomy bag; relatively simple and dependable. |
| Orthotopic neobladder | Larger bowel segment is reshaped into reservoir and connected to urethra | Voiding by abdominal/pelvic-floor coordination; night leakage and incomplete emptying can occur. |
| Continent cutaneous reservoir | Internal pouch drains through a small abdominal channel using a catheter | Requires reliable self-catheterisation several times a day. |
Chemotherapy before surgery
Cisplatin-based neoadjuvant chemotherapy improves survival in eligible muscle-invasive disease and is commonly recommended before cystectomy. Some patients cannot receive cisplatin because of kidney, hearing, neuropathy or general fitness limitations. The oncology team determines eligibility.
Hospital stay and early recovery
Cystectomy is a large abdominal operation. Enhanced-recovery pathways encourage early mobilization, careful fluid management, early feeding when safe and multimodal pain control. Hospital stay varies, often around a week or longer depending on recovery and complications. Ureteric stents, drains and catheters may be used temporarily depending on the diversion.
Major risks
- Bleeding and transfusion.
- Infection, urine leak or wound problems.
- Ileus or bowel obstruction.
- Blood clots and pulmonary embolism.
- Heart or lung complications.
- Urinary-tract infection or kidney obstruction from later ureteroenteric narrowing.
- Metabolic and nutritional consequences of using bowel for urinary diversion.
- Sexual dysfunction and fertility loss.
Sexual function after cystectomy
Men commonly experience erectile dysfunction because pelvic nerves can be affected and the prostate/seminal vesicles are removed. Selected nerve-sparing techniques may preserve function in some patients when cancer location allows. Women can experience vaginal shortening, dryness, pelvic-floor changes and sexual dysfunction. Sexual rehabilitation should be discussed proactively.
How long does full recovery take?
Basic mobility improves over weeks, but fatigue, appetite, bowel rhythm and adaptation to a stoma or neobladder often take two to three months or longer. Return to heavy work and strenuous exercise is gradual. Nutritional recovery is especially important if chemotherapy was given before surgery.
Cancer follow-up after cystectomy
Follow-up includes imaging, kidney function and monitoring for recurrence. Patients with urinary diversions also need assessment for infections, stones, vitamin or metabolic problems and diversion-specific complications. A neobladder or conduit remains a lifelong urological system that deserves surveillance even after cancer treatment is complete.
Red flags after discharge
- Fever, rigors or worsening wound redness.
- Persistent vomiting, abdominal distension or inability to pass stool/gas.
- Little or no urine from the stoma/neobladder with pain or illness.
- New calf swelling, chest pain or breathlessness.
- Heavy bleeding, severe dehydration or confusion.
What happens during radical cystectomy?
In men, standard surgery usually removes the bladder and prostate, with variations possible in carefully selected cases. In women, the organs removed depend on tumour location, anatomy and the planned reconstructive approach. Pelvic lymph nodes are removed for staging and cancer control. The urinary tract must then be reconstructed using bowel — most commonly an ileal conduit or, in selected patients, an orthotopic neobladder. Continent cutaneous reservoirs are another option in some centres.
Open and robotic approaches are both used. The choice of approach should not change the cancer operation that needs to be performed. The priorities are complete tumour removal, appropriate lymph-node dissection, safe urinary diversion and management of bowel and urinary reconstruction.
What recovery continues after discharge?
Cystectomy is major abdominal surgery. Early walking, breathing exercises, prevention of blood clots, gradual return of bowel function and careful fluid/electrolyte management are important. Stoma or neobladder education begins before discharge. Fatigue can last for weeks and nutritional intake may take time to normalize. Readmission can occur for infection, dehydration, bowel problems, urinary leak or blood clots, so clear discharge instructions are essential.
Long-term follow-up is not only about cancer scans. Kidney function, hydronephrosis, urinary infections, stoma or continence issues, metabolic changes and vitamin B12 can require surveillance. Sexual and reproductive effects should be discussed before surgery whenever possible.
Choosing the urinary diversion is a separate major decision
Removing the bladder and choosing how urine will be diverted are related but distinct decisions. An ileal conduit is usually simpler to learn and has reliable drainage but requires a stoma appliance. A neobladder can allow voiding per urethra in selected patients but requires training, carries a greater chance of night-time leakage or incomplete emptying, and sometimes requires intermittent catheterisation. Continent cutaneous reservoirs are another option in selected centres.
Cancer location, kidney and liver function, bowel health, urethral involvement, manual dexterity, motivation and the patient’s priorities all influence the choice. A diversion should not be selected only because it sounds “more natural” or “less invasive.”
The pathology after cystectomy can change the next treatment
The cystectomy specimen reports final T stage, lymph-node status, margins, carcinoma in situ, lymphovascular invasion and variant histology. Patients who remain at high risk of recurrence after surgery may be candidates for additional systemic treatment depending on what they received before surgery and their final pathology. Follow-up therefore begins with understanding the postoperative pathology, not simply with recovery from the operation.
Recovery is major abdominal surgery even when the approach is robotic
Robotic cystectomy may reduce incision size and blood loss in some settings, but the internal operation remains extensive: the bladder is removed, lymph nodes are dissected and bowel is used to create a urinary diversion. Ileus, infection, clots, dehydration and readmission remain important risks. Enhanced-recovery pathways focus on early mobilisation, nutrition, multimodal pain control and timely removal of tubes where safe.
Patients should judge recovery by return of strength, nutrition, bowel function and independence with the diversion, not simply by the skin-incision size.
Consultation checklist
- TURBT pathology and staging report.
- CT/MRI staging images.
- Neoadjuvant chemotherapy records if given.
- Kidney function, hearing and neuropathy history.
- Previous abdominal/pelvic surgery and bowel disease.
- Stoma or neobladder counselling notes.
- Current medicines and anticoagulants.
- Baseline sexual function, manual dexterity and social support.
FAQs
Is bladder removal always necessary for muscle-invasive cancer?
No. Selected patients can receive trimodality bladder-preserving therapy, but cystectomy remains a standard curative option and may be preferred depending on tumour features.
Can I choose a neobladder?
Possibly, but urethral cancer risk, kidney/liver function, bowel health, continence potential, manual dexterity and willingness to catheterise if needed all matter.
Will I need a bag forever after ileal conduit?
Yes. An ileal conduit drains continuously into an external urostomy pouch.
Can cystectomy be done robotically?
Yes in experienced centres. Robotic cystectomy is a minimally invasive approach to the extirpative surgery, but urinary diversion may be constructed intracorporeally or extracorporeally and the operation remains major surgery.
How soon can I return to normal life?
Many daily activities return over 6–12 weeks, but full strength and adaptation can take longer, especially after chemotherapy or complications.
Related reading
- Muscle-Invasive Bladder Cancer
- Ileal Conduit Explained
- Neobladder Surgery Explained
- BCG Therapy for Bladder Cancer
- Uro-Oncology Second Opinion: When Should You Take One?
- Bladder Preservation vs Radical Cystectomy
- Urologist in Latur
References
- European Association of Urology (EAU). EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. 2026 edition https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
- British Association of Urological Surgeons (BAUS). Radical cystectomy and urinary diversion patient information https://www.baus.org.uk/
- National Cancer Institute. Bladder Cancer Treatment (PDQ®)–Patient Version https://www.cancer.gov/types/bladder/patient/bladder-treatment-pdq
- American Urological Association/ASCO/ASTRO/SUO. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer Guideline (2017; amended 2024) https://www.auanet.org/guidelines-and-quality/guidelines/muscle-invasive-bladder-cancer